Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C13H15NO6 |
| Molecular Weight | 281.2613 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](OC(=O)C1=C(OC(C)=O)C=CC=C1)[C@H](N)C(O)=O
InChI
InChIKey=KUUVQWCRENBXIV-HQJQHLMTSA-N
InChI=1S/C13H15NO6/c1-7(11(14)12(16)17)19-13(18)9-5-3-4-6-10(9)20-8(2)15/h3-7,11H,14H2,1-2H3,(H,16,17)/t7-,11+/m1/s1
| Molecular Formula | C13H15NO6 |
| Molecular Weight | 281.2613 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:36:50 GMT 2023
by
admin
on
Sat Dec 16 11:36:50 GMT 2023
|
| Record UNII |
362NTC92GU
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
362NTC92GU
Created by
admin on Sat Dec 16 11:36:50 GMT 2023 , Edited by admin on Sat Dec 16 11:36:50 GMT 2023
|
PRIMARY | |||
|
57343743
Created by
admin on Sat Dec 16 11:36:50 GMT 2023 , Edited by admin on Sat Dec 16 11:36:50 GMT 2023
|
PRIMARY | |||
|
852055-88-0
Created by
admin on Sat Dec 16 11:36:50 GMT 2023 , Edited by admin on Sat Dec 16 11:36:50 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Platrol has demonstrated 40% more efficacy and negligible toxicity resulting in higher therapeutic index compared to Aspirin, Clopidogrel and other anti-platelet drugs in clinical trials. Surprisingly, its inherent sustained release property makes Platrol even better as a long-term cardio-protective drug. Pioneering studies by Garret Fitzgerald at the University of Pennsylvania and other scientists in the 80's have shown that a controlled release formulation of Aspirin at the correct release rate will result in sustained specific irreversible acetylation of platelets as they pass through the portal circulation. This will enhance action of Aspirin in endothelium, but mitigating its anti-Aspirin like activity if released into the systemic circulation.
|
